Abeona therapeutics announces submission of briefing package for pre-biologics license application (bla) meeting with fda in august 2023

Cleveland, july 28, 2023 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo) today announced that it has completed the submission of the briefing package to the u.s. food and drug administration (fda) for the company's pre-biologics license application (bla) meeting in august 2023. the purpose of the pre-bla meeting is to discuss with the fda the format, content, and acceptability of the anticipated bla for eb-101, abeona's investigational autologous, engineered cell therapy for recessive dystrophic epidermolysis bullosa.
ABEO Ratings Summary
ABEO Quant Ranking